Simplification of hepatitis C care: changes in the provider landscape after direct-acting antivirals and their impact on treatment

Shashi Kapadia used a national administrative dataset to characterize changes in the Hepatitis C (HCV) provider landscape, comparing the period before direct acting antivirals (DAAs) and after DAAs. Using this dataset, he assessed the changes in the number and types of providers offering HCV-testing and treatment, examined the HCV testing and treatment volume across providers, and compared the rate of treatment completion for patients treated by providers with different volumes.

Shashi Kapadia is an infectious diseases physician and health services researcher whose work has focused on the equitable delivery of healthcare for people who use drugs and people living with HIV. He conducts both observational and interventional clinical research related to the uptake of hepatitis C virus treatment for this population. He has skills in observational clinical-epidemiologic research, in health economic and policy analyses, and has experience with clinical trials. Specific ongoing projects include 1) examining the uptake of hepatitis C virus testing and treatment among primary care and substance use treatment providers; 2) testing the effectiveness and measuring the cost of an intervention to co-locate hepatitis C treatment in syringe service programs; and 3) testing the safety and effectiveness of rapid treatment starts for hepatitis C among people who inject drugs. Kapadia is affiliated with the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) and the Center for Health Equity, both based at Weill Cornell.